Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

v3.24.1.1.u2
Income Taxes (Tables)
12 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Provision (Benefit) for Income Taxes
The components of the Company’s income tax provision (benefit) attributable to operations are as follows:
Year ended March 31,
2024 2023 2022
Current:
U.S. federal $ —  $ (38) $ 236 
State and local —  637  703 
Non-U.S. 8,262  10,313  7,439 
8,262  10,912  8,378 
Deferred:
U.S. federal 5,925  3,026  1,485 
State and local 5,491  (3,430) (1,350)
Non-U.S. (4,361) (5,362) (110)
7,055  (5,766) 25 
Income tax provision $ 15,317  $ 5,146  $ 8,403 
Reconciliation of Income Tax Expense Between Statutory U S Income Tax Rate With Actual Income Tax Provision
A reconciliation of income tax expense using the statutory U.S. income tax rate compared with the actual income tax provision follows:
Year ended March 31,
2024 2023 2022
Statutory federal income taxes $ (85,077) $ 4,650  $ 9,256 
State income taxes, net of federal benefit —  77  938 
State rate remeasurement 1,680  (2,992) — 
Non-deductible expenses 176  67  2,891 
Disallowed executive compensation 1,145  1,070  — 
Excess deductions for stock compensation 2,783  1,167  (9,946)
Foreign income inclusion, net —  3,926  — 
Foreign rate differential (544) (2,682) (1,554)
Impairment of goodwill 64,346  —  — 
Change in Mobile Posse earn-out —  —  — 
Change in Fyber earn-out —  —  10,500 
Change in AdColony earn-out —  —  (1,872)
Research and development tax credit (721) (3,000) — 
Change in uncertain tax liability 144  600  52 
Change in valuation allowance 29,010  6,500  (1,503)
Return-to-provision adjustments 2,375  (4,237) (454)
Other miscellaneous —  —  95 
Income tax provision $ 15,317  $ 5,146  $ 8,403 
Schedule of Deferred Tax Assets and Liabilities
Deferred income tax assets and liabilities consist of the following:
Year ended March 31,
2024 2023 2022
Deferred income tax assets
Net operating loss carry-forward $ 74,997  $ 63,660  $ 76,219 
Stock-based compensation 6,527  7,009  3,765 
Accrued compensation 219  1,562  3,724 
Capitalized research and experimentation expenses 2,311  4,965  — 
Disallowed Interest
7,886  1,366  1,700 
Gross deferred income tax assets 91,940  78,562  85,408 
Valuation allowance (55,852) (25,921) (19,914)
Net deferred income tax assets 36,088  52,641  65,494 
Deferred income tax liabilities
Depreciation and amortization (1,427) (2,063) (5,795)
Intangibles and goodwill (55,085) (64,518) (79,675)
Net deferred income tax assets (liabilities) $ (20,424) $ (13,940) $ (19,976)
Schedule of Operating Loss Carryforwards
The following details the scheduled expiration dates of the Company’s net operating loss (NOL) carryforwards:
2025 Through 2034 2035 Through 2044 Indefinite Total
U.S. federal NOLs $ 48,115  $ 53,556  $ 101,671 
State taxing jurisdictions NOLs 8,695  121,466  29,211  159,372 
Non-U.S. NOLs 154,548  154,548 
Total, net $ 8,695  $ 169,581  $ 237,315  $ 415,591 
Schedule of Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits
A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended March 31, 2024, 2023, and 2022, is as follows:
Year ended March 31,
  2024 2023 2022
Balance at April 1 $ 2,024  $ 1,424  $ 1,372 
Additions for tax positions of prior years 144  600  52 
Reductions for tax positions of prior years —  —  — 
Balance at March 31 $ 2,168  $ 2,024  $ 1,424